CStone has submitted a clinical trial application in Australia for CS2009, a novel trispecific antibody targeting PD-1, VEGF, and CTLA-4.

This approval allows the company to commence its First-In-Human (FIH) Phase 1 therapeutic clinical trial of 177Lu-labelled RAD 202 aimed at treating HER2-expressing solid tumors.

The FDA has authorized Zepbound® (tirzepatide) as the first and sole prescription treatment for moderate to severe obstructive sleep apnea in obese adults.

The FDA has authorized Alhemo® injection for once-daily use to prevent or lessen bleeding episodes in adults and children aged 12 and up who have hemophilia A or B with inhibitors.

The U.S. FDA has approved the use of Pfizer's BRAFTOVI® combination therapy as a first-line treatment for metastatic colorectal cancer with BRAF V600E mutations.

Vertex has received US FDA approval for ALYFTREK™, a new once-daily CFTR modulator aimed at treating cystic fibrosis.

the Antibody-Drug Conjugates (ADCs) market has entered a new phase of rapid growth since 2019, maintaining an annual growth rate exceeding 30%.

Marengo has dosed its initial patient in the Phase 2 clinical trial of Invikafusp Alfa (STAR0602) targeting PD-1 resistant tumors and is extending the study to Europe.

JCR Pharmaceuticals launches Phase III trial for JR-142 in Japan, a long-lasting growth hormone treatment.

Merck signs exclusive global licensing deal for LM-299, a candidate bispecific antibody targeting PD-1 and VEGF.

InflaRx reports the initial patient has been treated in the Phase 2a trial for the oral C5aR inhibitor INF904.

Novo Nordisk A/S: In the REDEFINE 1 trial, CagriSema shows better weight loss results for adults with obesity or excess weight.